Colorectal Cancer

Pipeline Assessment and Market Forecasts to 2020

Product Code GDA02644
Publication Date October 2010
Publisher GlobalData
Product Type Report
Pages 137
ISBN Number not applicable
Change currency
PDF £2,215.00 €2,667 $3,502 BUY >
Order by fax
Ask a question about this product > Receive product alerts > Call now +44 20 7060 7474

Colorectal Cancer

Pipeline Assessment and Market Forecasts to 2020

Colorectal Cancer - Pipeline Assessment and Market Forecasts to 2020

Summary

GlobalData, the industry analysis specialist, has released its new report, Colorectal Cancer - Pipeline Assessment and Market Forecasts to 2020. The report is an essential source of information and analysis on the global Colorectal Cancer therapeutics market. The report identifies the key trends shaping and driving the global Colorectal Cancer therapeutics market. The report also provides insights into the competitive landscape and the emerging players expected to significantly alter the positions of the existing market leaders. Most importantly, the report provides valuable insights into the pipeline products within the global Colorectal Cancer sector.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

GlobalData analysis found that, in 2009, the global colorectal cancer therapeutics market was worth $7.0 billion. Between 2001 and 2009, the market grew at a rate of 27.6%. By 2020, the market is expected to be worth $8.8 billion, indicating a Compound Annual Growth Rate (CAGR) of 2.1% between 2009 and 2020. In 2009, the US was the leading market in the global colorectal cancer therapeutics market with an estimated market share of 54.8%. Japan was the second leading market with an approximate market share of 13.4%, closely followed by France with an approximate market share of 9.6%.

In 2009, bevacizumab was the leading drug with approximate sales worth $2.5 billion and a market share of 35.1%. Oxaliplatin was the second leading drug with approximate sales of $1.3 billion and a market share of 18.6%. Cetuximab, the EGFR inhibitor, was the third leading drug with an approximate sales value of $887m and a market share of 12.7%.

Scope

The scope of the report includes--

- Annualized global Colorectal Cancer therapeutics market revenue data from 2001 to 2009, forecast for 11 years to 2020.

- Geographies covered in this report include the United States (US), the United Kingdom (UK), Italy, Spain, Germany, France Japan and BRIC countries that include Brazil, Russia, India and China.

- Pipeline analysis data providing a split across different phases, mechanisms of action being developed and emerging trends. The key classes of mechanism of action include EGFR inhibitors, VEGF inhibitors, monoclonal antibodies, angiogenesis inhibitors, immunotherapies, antimetabolites, fluoropyrimidine modulators, tyrosine kinase inhibitors, folate analogs, topoisomerase 1 inhibitors, insulin-like growth factor receptor (IGFR) inhibitors, pathway inhibitors, TRAIL receptor 1 antibodies and apoptosis inducers.

- Analysis of the current and future market competition in the global Colorectal Cancer therapeutics market. The key future market players covered are Hoffmann-La Roche Ltd, Bristol-Myers Squibb, Eli Lilly, Sanofi-Aventis, Debiopharm Group, Merck KGaA, Regeneron, Vaccinogen, Inc., Oxford BioMedica, Auron Healthcare GmbH, AEterna Zentaris, Keryx, Abbott Laboratories, Pfizer Inc and Light Sciences Oncology, Inc.

- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.

- Key topics covered include a strategic competitor assessment, a market characterization, the unmet needs and the implications for the Colorectal Cancer market

Reasons to buy

The report will enhance your decision making capability. It will allow you to:

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipelines.
  • Develop business strategies by understanding the trends shaping and driving the global Colorectal Cancer therapeutics market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to affect the global Colorectal Cancer therapeutics market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify the emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present the best opportunities for consolidation, investments and strategic partnerships.
  • What's the next big thing in the global Colorectal Cancer therapeutics market landscape? Identify, understand and capitalize

Contents

  • 1 Table of contents
    • 1.1 List of Tables
    • 1.2 List of Figures
  • 2 Disease Overview
    • 2.1 Overview
    • 2.2 Epidemiology
    • 2.3 Etiology
    • 2.4 Symptoms
      • 2.4.1 Colon Cancer
      • 2.4.2 Rectal Cancer
    • 2.5 Diagnosis
      • 2.5.1 FOBT
      • 2.5.2 Endoscopy
      • 2.5.3 Optical Colonoscopy
      • 2.5.4 Virtual Colonoscopy
      • 2.5.5 Double Contrast Barium Enema (DCBE)
    • 2.6 Pathology
      • 2.6.1 Grading
    • 2.7 Treatment
      • 2.7.1 Colon Cancer Treatment by Stage
      • 2.7.2 Rectal Cancer Treatment by Stage
      • 2.7.3 Chemotherapy Options
  • 3 Market Characterization
    • 3.1 Global
      • 3.1.1 Market Size
      • 3.1.2 Drivers and Barriers
      • 3.1.3 Forecasts
      • 3.1.4 Drug Sales
    • 3.2 Key Takeaway
  • 4 Competitor Assessment
    • 4.1 Strategic Competitor Assessment
      • 4.1.1 Overview
      • 4.1.2 Benchmarking
      • 4.1.3 Current Competitor Assessment
    • 4.2 Product Profiles
      • 4.2.1 Avastin (bevacizumab)
      • 4.2.2 Erbitux (cetuximab)
      • 4.2.3 Xeloda (capecitabine)
      • 4.2.4 Vectibix (panitumumab)
      • 4.2.5 Eloxatin (oxaliplatin)
      • 4.2.6 Camptosar (irinotecan)
      • 4.2.7 Fluorouracil (5-FU)
      • 4.2.8 Leucovorin (folinic acid)
    • 4.3 Key Takeaway
  • 5 Pipeline Assessment
    • 5.1 Overview
    • 5.2 Pipeline Analysis by Phase of Development
    • 5.3 Pipeline by Mechanism of Action
    • 5.4 Strategic Pipeline Assessment
      • 5.4.1 Technology Trends Analytical Framework
    • 5.5 Trends in Colorectal Cancer Pipeline
      • 5.5.1 Increase in the Number of Vaccines in R&D Targeted at Stage III Colorectal Cancer
      • 5.5.2 Novel First-in-Class Molecules in Late-stage Clinical Development Strengthening the Pipeline
      • 5.5.3 Failure of key Molecules in Phase II and Phase III Development
    • 5.6 Partners in Development
      • 5.6.1 Licensing Agreements by Phase of Development
      • 5.6.2 Licensing Agreements by Geography
      • 5.6.3 Licensing Agreements: Colorectal Cancer Screening / Diagnostic Technology
    • 5.7 Most Promising Drugs' Profiles
      • 5.7.1 Aflibercept
      • 5.7.2 Brivanib
      • 5.7.3 OncoVAX
      • 5.7.4 TroVax
      • 5.7.5 KRX-0401 (Perifosine)
    • 5.8 Colorectal Cancer Pipeline – Preclinical Phase
    • 5.9 Colorectal Cancer Pipeline – Phase I
    • 5.10 Colorectal Cancer Pipeline – Phase II
    • 5.11 Colorectal Cancer Pipeline – Phase III
    • 5.12 Key Takeaway
  • 6 Unmet Need and Target Product Profile
    • 6.1 Unmet Need
    • 6.2 Opportunity for Target Product
    • 6.3 Key Takeaway
  • 7 Strategic Assessment
    • 7.1 Key Events Impacting the Future Market
    • 7.2 Market Impact Analysis
    • 7.3 Future Market Scenario
    • 7.4 Company Analysis
      • 7.4.1 Market Leadership
      • 7.4.2 Future Players in the Market
    • 7.5 Key Takeaway
  • 8 Company Profiles
    • 8.1 F. Hoffmann La Roche
      • 8.1.1 Business Description
      • 8.1.2 Financial Overview
      • 8.1.3 SWOT Analysis
    • 8.2 Bristol-Myers Squibb
      • 8.2.1 Business Description
      • 8.2.2 Financial Overview
      • 8.2.3 SWOT Analysis
    • 8.3 Sanofi-Aventis
      • 8.3.1 Business Description
      • 8.3.2 Financial Overview
      • 8.3.3 SWOT Analysis
    • 8.4 Debiopharm Group
      • 8.4.1 Business Description
    • 8.5 Merck KGaA
      • 8.5.1 Business Description
      • 8.5.2 Financial Overview
      • 8.5.3 SWOT Analysis
    • 8.6 Regeneron
      • 8.6.1 Business Description
      • 8.6.2 Financial Overview
      • 8.6.3 SWOT Analysis
    • 8.7 Vaccinogen BD
      • 8.7.1 Overview
      • 8.7.2 SWOT Analysis
    • 8.8 Oxford BioMedica
      • 8.8.1 Business Description
      • 8.8.2 Financial Overview
      • 8.8.3 SWOT Analysis
    • 8.9 Auron Healthcare GmbH
      • 8.9.1 Company Overview
    • 8.10 AEterna Zentaris
      • 8.10.1 Business Description
      • 8.10.2 Financial Overview
      • 8.10.3 SWOT Analysis
    • 8.11 Keryx
      • 8.11.1 Business Description
      • 8.11.2 Financial Overview
      • 8.11.3 SWOT Anlaysis
    • 8.12 Abbott Laboratories
      • 8.12.1 Business Description
      • 8.12.2 Financial Performance
      • 8.12.3 SWOT Analysis
    • 8.13 Pfizer
      • 8.13.1 Business Description
      • 8.13.2 Financial Overview
      • 8.13.3 SWOT Analysis
    • 8.14 Light Sciences Oncology, Inc
      • 8.14.1 Business Description
      • 8.14.2 Financial Overview
      • 8.14.3 SWOT Analysis
  • 9 Appendix
    • 9.1 Market Definitions
    • 9.2 Scope of Pipeline Research
    • 9.3 Abbreviations
    • 9.4 Research Methodology
      • 9.4.1 Coverage
      • 9.4.2 Secondary Research
      • 9.4.3 Forecasting
      • 9.4.4 Primary Research
      • 9.4.5 Expert Panel validation
      • 9.4.6 Contact Us
      • 9.4.7 Disclaimer
      • 9.4.8 Sources
  • List of Tables
    • Table 1: Colorectal Cancer Therapeutics Market, Global, Staging of Colorectal Cancer, 2010
    • Table 2: Colorectal Cancer Therapeutics Market, Global, WHO Classification of Colorectal Carcinomas, 2010
    • Table 3: Colorectal Cancer Therapeutics Market, Global, Sales Value ($bn), 2001–2009
    • Table 4: Colorectal Cancer Therapeutics Market, Global, Annual Cost of Therapy ($), 2001–2009
    • Table 5: Colorectal Cancer Therapeutics Market, Global, Patient Volume ('000), 2001–2009
    • Table 6: Colorectal Cancer Therapeutics Market, Global, Treatment Usage Patterns, 2001–2009
    • Table 7: Colorectal Cancer Therapeutics Market, Global, Sales Value ($bn), 2009–2020
    • Table 8: Colorectal Cancer Therapeutics Market, Global, Annual Cost of Therapy ($), 2009–2020
    • Table 9: Colorectal Cancer Therapeutics Market, Global, Patient Volume ('000), 2009–2020
    • Table 10: Colorectal Cancer Therapeutics Market, Global, Treatment Usage Patterns (millions), 2009–2020
    • Table 11: Colorectal Cancer Therapeutics Market, Global, Drug Sales ($m), 2001-2010
    • Table 12: Colorectal Cancer Therapeutics Market, Global, Drug Sales ($m), 2001-2020
    • Table 13: Colorectal Cancer, Global, Safety Profile of Standard Treatment, 2010
    • Table 14: Colorectal Cancer Therapeutics Market, Global, Benchmarking Major Marketed Products, 2010
    • Table 15: Colorectal Cancer, Global, Avastin Adverse Effects Incidence, 2010
    • Table 16: Colorectal Cancer Therapeutics Market, Global, Erbitux, Incidence of Adverse Effects, 2010
    • Table 17: Colorectal Cancer Therapeutics Market, Global, Xeloda, Adverse Effects Incidence, 2010
    • Table 18: Colorectal Cancer Therapeutics Market, Global, Vectibix, PRECEPT Interim Results, 2010
    • Table 19: Colorectal Cancer Therapeutics Market, Global, Vectibix, Incidence of Adverse Events, 2010
    • Table 20: Colorectal Cancer Therapeutics Market, Global, Eloxatin, Efficacy, 2010
    • Table 21: Colorectal Cancer Therapeutics Market, Global, Eloxatin, Incidence of Adverse Events, 2010
    • Table 22: Colorectal Cancer Therapeutics Market, Global, Technology Licensing Agreements Description, 2010
    • Table 23: Colorectal Cancer Therapeutics Market, Global, Preclinical Phase Pipeline, July 2010
    • Table 24: Colorectal Cancer, Global, Phase I Pipeline, July 2010
    • Table 25: Colorectal Cancer, Global, Phase II Pipeline, July 2010
    • Table 26: Colorectal Cancer, Global, Phase III Pipeline, July 2010
    • Table 27: Colorectal Cancer Therapeutics Market, Global, Commonly Prescribed Treatment Options, 2010
  • List of Figures
    • Figure 1: Colorectal Cancer Therapeutics Market, Global, Sales Value ($bn), 2001–2009
    • Figure 2: Colorectal Cancer Therapeutics Market, Global, Annual Cost of Therapy ($), 2001–2009
    • Figure 3: Colorectal Cancer Therapeutics Market, Global, Patient Volume, 2001–2009
    • Figure 4: Colorectal Cancer Therapeutics Market, Global, Treatment Usage Patterns, 2001–2009
    • Figure 5: Colorectal Cancer Therapeutics Market, Global, Market Drivers and Restraints, 2009
    • Figure 6: Colorectal Cancer Therapeutics Market, Global, The Impact of Historical Events on the Market, 2010
    • Figure 7: Colorectal Cancer Therapeutics Market, Global, Sales Value ($bn), 2009–2020
    • Figure 8: Colorectal Cancer Therapeutics Market, Global, Annual Cost of Therapy ($), 2009–2020
    • Figure 9: Colorectal Cancer Therapeutics Market, Global, Patient Volume (absolute), 2009–2020
    • Figure 10: Colorectal Cancer Therapeutics Market, Global, Treatment Usage Patterns, 2009–2020
    • Figure 11: Colorectal Cancer Therapeutics Market, Global, Future Market Drivers and Restraints, 2009–2020
    • Figure 12: Colorectal Cancer Therapeutics Market, Global, Drug Sales ($m), 2001-2020
    • Figure 13: Colorectal Cancer Therapeutics Market, Global, Market Breakdown by Drug Sales (%), 2009
    • Figure 14: Colorectal Cancer Therapeutics Market, Global, Clinical Endpoints for Benchmarking, 2010
    • Figure 15: Colorectal Cancer Therapeutics Market, Global, Strategic Competitor Assessment of Major Marketed Drugs, 2010
    • Figure 16: Colorectal Cancer Therapeutics Market, Global, Avastin, Life Cyle Management Activities, 2004–2010
    • Figure 17: Colorectal Cancer Therapeutics Market, Global, Erbitux, Life Cycle Management Activities, 2004–2010
    • Figure 18: Colorectal Cancer Therapeutics Market, Global, Xeloda, Chemical Structure, 2010
    • Figure 19: Colorectal Cancer Therapeutics Market, Global, Xeloda, Life Cycle Management Activities, 2010
    • Figure 20: Colorectal Cancer Therapeutics Market, Global, Vectibix, Life Cyle Management Activities, 2010
    • Figure 21: Colorectal Cancer Therapeutics Market, Global, Eloxatin, Chemical Structure, 2010
    • Figure 22: Colorectal Cancer Therapeutics Market, Global, Eloxatin, Life Cyle Management Activities, 2010
    • Figure 23: Colorectal Cancer Therapeutics Market, Global, Camptosar, Chemical Structure
    • Figure 24: Colorectal Cancer Therapeutics Market, Global, Camptosar, Life Cyle Management Activities, 2010
    • Figure 25: Colorectal Cancer Therapeutics Market, Global, Fluorouracil, Chemical Structure
    • Figure 26: Colorectal Cancer Therapeutics Market, Global, Leucovorin, Chemical Structure
    • Figure 27: Colorectal Cancer Therapeutics Market, Global, Clinical Trials by Therapy (%), 2010
    • Figure 28: Colorectal Cancer Therapeutics Market, Global, Clinical Trials by Phase of Development (%), 2010
    • Figure 29: Colorectal Cancer Therapeutics Market, Global, Pipeline by Mechanism of Action, 2010
    • Figure 30: Colorectal Cancer Therapeutics Market, Global, Technology Trends Analytic Framework of Pipeline Drugs, 2010
    • Figure 31: Colorectal Cancer Therapeutics Market, Global, Technology Trends Description of Pipeline Drugs, 2010
    • Figure 32: Colorectal Cancer Therapeutics Market, Global, Licensing Agreements by Phase of Development (%), 2004-2010
    • Figure 33: Colorectal Cancer Therapeutics Market, Global, Licensing Agreements by Geography (%), 2010
    • Figure 34: Colorectal Cancer Therapeutics Market, Global, Licensing Agreements by Screening/Diagnostic Technology (%), 2010
    • Figure 35: Colorectal Cancer Therapeutics Market, Global, Brivanib Chemical Structure, 2010
    • Figure 36: Colorectal Cancer Therapeutics Market, Global, Perifosine Chemical Structure, 2010
    • Figure 37: Colorectal Cancer Therapeutics Market, Global, Median Overall Survival for Metastatic Colorectal Cancer Patients (months), 2010
    • Figure 38: Colorectal Cancer Therapeutics Market, Unmet Need by Geography, 2010
    • Figure 39: Colorectal Cancer, Global, Key Events Impacting the Future Market
    • Figure 40: Colorectal Cancer Therapeutics Market, Global, Implications for Future Market Competition, 2010
    • Figure 41: GlobalData Market Forecasting Model